World one-hundred days after COVID-19 outbreak: Incidence, case fatality rate, and trend

Ali Kazemi-Karyani, Roya Safari-Faramani, Saeed Amini, Vajiheh Ramezani-Doroh, Farzan Berenjian, Mohammad Yahyavi Dizaj, Reza Hashempour, Jafar Yahyavi Dizaj

Abstract:
BACKGROUND: The prevalence of viral diseases is on the rise and has caused many problems for public health. COVID-19 is a new viral outbreak in the world. This study aimed to investigate the trends of incidence and case fatality rate (CFR) of COVID-19 in the world by April 30, 2020.

METHODS: This was a descriptive-analytical study. We investigated the number of cases and deaths in 35 selected countries and regions of the WHO that had at least 10,000 cases by the time of the study. In addition, the incidence and CFR of COVID-19 were investigated. Finally, time trends of the number of cases, deaths, and CFR were investigated using ordinary least squares regression models.

RESULTS: The total number of confirmed cases of COVID-19 was 3,090,184. The European region had the highest number of COVID-19 patients (1,434,649 [46.43%]). Ukraine with 10,406 and the USA with 1,003,974 cases have reported the lowest and highest confirmed cases, respectively. In addition, the European region and the African region with 157.13 and 2.50 patients per 100,000 population had the highest and the lowest incidence rate, respectively. India (2.44) and Spain (455.69) had the lowest and the highest incidence rate per 100,000 population, respectively. In the world, 217,759 deaths have happened, of which 135,961 (62.44%) were reported in the European region. Furthermore, the USA had the highest number of deaths (52,428) due to COVID-19. CFR was 7.05% in the world, which ranged from 3.74% in the African region and 9.48% in the European region. The number of patients and deaths due to COVID-19 had increasing trends in all countries, and the trend of CFR just for Iran and Ukraine was negative.

CONCLUSION: The countries had different trends in the morbidity and mortality of COVID-19. However, regarding the increasing trend of the disease in the world, it will be more important to rely on public prevention strategies. It is necessary to apply and continue public health policies at national and global levels till the control of the disease.

Keywords: Case fatality rate, COVID-19, incidence, outbreak, trend

Introduction

According to WHO reports, the prevalence of viral diseases is on the rise and has caused many problems for public health. In the two recent decades, several viral epidemics such as SARS-CoV (2002–2003) and H1N1 Influenza (2009) have been reported.[1] In December 2019, a number of patients with pneumonia symptoms caused by a newly identified β-coronavirus were discovered in Wuhan, China.[2] Within a month, the disease spread rapidly; the coincidence of the virus with the start of the new year and increase in travels increased the speed of its spread and transmission between cities and different countries.[3] This coronavirus was first named as the...
2019-novel coronavirus (2019-nCoV) on January 12, 2020, by the World Health Organization (WHO). Then, the WHO introduced it as “COVID-19,” and some researchers have named it as SARS-CoV-2. Chinese scientists quickly isolated a SARS-CoV-2 virus from a patient on January 7, 2020, to extract the genetic structure of SARS-CoV-2.[4] On January 30, 2020, the WHO announced the coronavirus outbreak as the sixth public health emergency after influenza (2009), polio (2014), Ebola in the west of Africa (2014), Zika (2016), and Ebola in Congo (2019).[5] Despite considerable efforts made to control the disease by the Chinese government, the disease spread rapidly and then it affected people in other countries of the world[6,7] until finally it was introduced as a pandemic disease on March 11, 2020.[8]

Based on the present epidemiological information, the disease incubation period varies from 1 to 14 days, usually 3–7 days. It is also contagious during the latency period.[7,9] Disease symptoms have a range of moderate to severe that include fever, cough, shortness of breath, and pneumonia. In severe cases, neurological, gastrointestinal, hepatic, and respiratory complications may occur. The disease is transmitted through respiratory droplets or direct contact with the infected person.[4,10] Another comprehensive study has reported that fever in 88.7% of patients, cough in 67.8% of patients, fatigue in 38.1% of patients, sputum in 33.4% of patients, shortness of breath in 18.6% of patients, sore throat in 13.9% of patients, and headache in 13.6% of patients are known as common symptoms.[4] COVID-19 is highly contagious in the elderly and people with underlying diseases, and the mean age of the patients varies from 47 to 59 years.[10] Its crude case fatality rate (CFR) has been reported as 2.3%, and the highest crude CFR (14.8%) is observed in the age group of above 80 years. The crude CFR for males and females is reported as 2.8% and 1.7%, respectively. The crude CFR has been approximately 0.9% in people without comorbidity.[11] The hospital transfer rate has been reported as 41%,[11] and the basic reproduction number or R0 has been estimated as 2.2 (90% interval: 1.4–3.8).[12] Others reported R0 to be 3.28 and it ranged from 1.4 to 6.5 with a mean of 2.79.[13]

The emergence of new epidemics has always had a heavy financial burden on the economies of the involved countries. The interference of an estimate indicated that the influenza pandemic could impose 700,000 deaths and 570 billion USD cost on countries.[14] It was also estimated that the Zika outbreak cost 2 billion dollars for the USA,[15,16] and the Ebola outbreak has imposed 53.19 billion dollars in the year 2014 on West Africa.[17] The epidemics of SARS in the year 2003 and influenza in the year 2013 have cost 30–100 billion and 40 billion dollars for China, respectively.[18] Other effects of the epidemics included effects on the pharmaceutical demand of countries, import and export, and impact on tourism. The results of studies have indicated that the final demand has increased 12% for pharmaceutical products and 13% for health care and has decreased 10% for wholesale trade, 10% for traveling by plane and train, 18% for food and beverages, 18% for accommodation, 14% for retail trade, and 38% for amusement and recreation activities.[19] The firms that have been most affected included those relating to transportation, tourism, fashion, and agro-food.[20] According to the OECD, gross domestic product will decrease by a half percent in the year 2020 and will reach 2.4%, and it may also be reduced and reach 1.5% if the COVID-19 outbreak continues a higher time period.[20]

Countries of the world are trying to cope with the possible devastating effects of COVID-19. Health organizations of countries through information flows and disease guidelines are trying to reduce the effect of this threat. Meanwhile, scientists around the world are researching tirelessly. Hence, the information on transmission, disease mechanism, clinical symptoms of the disease, methods of diagnosis, and appropriate strategies for the prevention and treatment of the disease are being developed.[1] In this situation, the rapid response of governments to overcome COVID-19 has an increasing importance.[20] Despite the actions taken, the disease is not yet controlled.

The number of confirmed cases and deaths has been variable from the beginning of the disease until April 30, 2020. According to the reports, by March 16, 2020, 174,961 patients with COVID 19 have been identified and 6,705 people have died from the disease.[21] In another study, it was reported that the total number of confirmed cases and total number of deaths until March 26, 2020, were 460,611 and 20,842, respectively.[22] The total number of confirmed cases in all the six regions is 3,089,733 cases, of which 71,839 cases have been newly approved. In addition, the total number of deaths in all regions is 217,756 cases, of which 9797 cases of it are new.[23] These statistics would help policymakers to make better decisions for resource allocation in health sector.[22] Although there are statistics regarding COVID-19, its morbidity and mortality trends have not been completely studied worldwide. This study aims to investigate the incidence of COVID-19 infections and deaths in the regions of WHO focusing on countries with a higher burden to obtain a complete picture of it, globally. In addition, we investigated CFR and its trend in the world to show the changes of this index during disease progress among the countries.
Methods

Data source
This was a descriptive-analytical and cross-sectional study performed in 2020 on the incidence and prevalence of COVID-19 morbidity and mortality until April 30, 2020. The data were extracted from the World Health Organization (WHO) reports which itself is on the basis of the countries members’ reports. These reports are continuous daily statistical reports related to total confirmed cases, total confirmed new cases, total deaths, and total new deaths, separated for countries and six regions of the WHO from January 20, 2020.

Analysis
As the COVID-19 incidence in the study time was very low in some countries, those countries were entered into the study which have reported more than 10,000 disease cases. Therefore, 34 countries were included in the final analysis. The mean and standard deviation (SD) of total cases and deaths were calculated. In addition, the incidence rate of COVID-19 was calculated per 100,000 populations for the WHO regions and the selected countries in the study period. The following formula was used to calculate the incidence:

Incidence rate: The number of patients during the study period/population during the study period × 100,000.

Furthermore, the CFR was obtained for the world, WHO regions, and the selected countries in the study period using the following formula:

\[ \text{CFR} = \frac{\text{Number of deaths in the study period}}{\text{Number of cases in the study period}} \times 100 \]

One of the other aims of this study was estimating the trends of total cases, total deaths, and CFR during the study time. The following regression formula was used to determine the trend of outcome variables in the different WHO regions and the selected countries.

\[ Y = \beta_0 + \beta_1 T. \]

Here, \( Y \) is the outcome variable (number of cases/deaths/CFR), \( \beta_0 \) is the intercept, \( \beta_1 \) is b-coefficient, and \( T \) is time (days). Indeed, \( \beta_1 \) shows the time trend of cases and deaths. We fitted two models for each country, one model for confirmed cases and another model for deaths. In addition, two models were fitted for the globe.

Results
All confirmed cases of COVID-19 disease until April 30, 2020, was 3,090,184 persons, and the mean (SD) of patient number in the countries of the world was 15,222.58 (76,180.64). The European region had the highest number of COVID-19 patients so that 1,434,649 (46.43%) patients were related to this region of the WHO. The lowest proportion of patients (0.82%) was reported in the African region, and the second-lowest reported cases of infection were reported in the South-East Asian Region. The highest and lowest mean of patients with 599.76 and 24,434.71 were related to countries covered by the African region and the region of the Americas, respectively. The COVID-19 incidence calculation indicated that the European region with 157.13 patients per 100,000 population had the highest and the African region with 2.50 patients per 100,000 population had the lowest incidence rate during the study period.

In terms of the number of deaths due to COVID-19 in the world, 217,759 deaths have happened, of which 135,961 (62.44%) were reported in the European region. In addition, the mean (SD) of deaths in the countries of the world was 1072.70 (5142.81). CFR of disease was 7.05% in the world, which ranged from 3.74% in the African region and 9.48% in the European region. Table 1 shows the total confirmed cases, incidence, total deaths, and CFR of coronaviruses in different regions of the WHO until April 30, 2020.

The comparison of selected countries indicated that Ukraine with 10,406 and the USA with 1,003,974 cases have reported the lowest and highest diagnosed cases of COVID-19, respectively. In this regard, Spain, Italy, Germany, the United Kingdom, and France were located in the next ranks. In terms of disease incidence, India (2.44) had the lowest and the Spain (455.69) had the highest incidence rate per 100,000 people. After Spain, Qatar, Belgium, Ireland, Switzerland, Italy, and the USA had the highest incidence rate.

Qatar and Singapore have reported 10 and 14 deaths, respectively. The highest number of deaths were reported from the USA (52,428), and then Italy, the United Kingdom, Spain, France, Belgium, Germany, and Iran. In terms of mortality, France had the highest CFR with 18.93 deaths per 100 COVID-19 confirmed cases. In the next ranks, CFRs in the United Kingdom, Belgium, Italy, and the Netherlands were 15.79%, 15.67%, 13.60%, and 12.14%, respectively. Qatar had the lowest CFR, and this rate in Singapore, Belarus, Saudi Arabia, and the United Arab Emirates was less than 1%. Table 2 indicates the total confirmed cases, incidence, total deaths, and CFR of coronaviruses in the selected countries.

Time trend assessment of the number of patients indicated that on an average, 27,003.95 cases have been identified on a daily basis, globally. The United Arab Emirates with 90.76 cases per day had the lowest increasing trend among the countries. After this country,
Singapore, Japan, and the Republic of Korea, on an average, have been reported 94.94, 116.81, and 148.08 new cases per day from the onset of the disease. On the other hand, the USA with a diagnosis of 8491.39 new cases in a day had the highest increasing trend. After that, Spain, Turkey, Italy, and Germany had the highest trend of confirmed cases.

Furthermore, the time trend of deaths due to COVID-19 indicated that all countries have had an increasing trend,
and an average of more than 1903 deaths have happened in the world each day. Some countries such as Singapore, Qatar, the United Arab Emirates, Belarus, and Japan have had fewer deaths over time, but on the other hand, the USA has had the highest rate of increase in death trend so that the average of 385.05 deaths daily due to COVID-19 disease has happened in this country. After the USA, Italy, Spain, France, the United Kingdom, and Iran had the highest slope of death since the beginning of the disease. The disease and death trend in all countries was statistically significant at the level of 0.001.

The time trend of CFR indicates that this rate has had an increasing trend in globe and on an average, every day 0.06 has been added to this index. Iran and Ukraine had a decreasing trend in CFR, but the trends were not statistically significant ($P > 0.05$). Singapore and Qatar had the lowest positive trends ($\beta = 0.004$). The highest increasing trend in CFR had happened in the Netherlands, Belgium, and the United Kingdom so that they had more than 0.2 increase in this index from the onset of the disease in these countries. Table 3 indicates the time trends of the total confirmed cases, the total deaths, and CFR of coronaviruses in the countries.

The figure related to death due to COVID-19 indicates that China has been able to reduce the slope of the disease at the end of the study time, but the USA, which has reported the first case of COVID-19 in the middle of the period, has had the most positive mortality slope so that this country has significant higher increasing trend than other countries. After the USA, Italy had the highest increasing slope of the deaths of the disease. In addition, Italy, the United Kingdom, Spain, and France are also placed in the next ranks of increasing slope of COVID-19-related deaths. Figure 2 indicates the trend of deaths due to COVID-19 in the countries.

Trend of CFR indicated that Iran had the highest CFR in the first days of disease. However, in the following days, the trend of CFR in this country has been decreasing. All countries in the end of the study period had an increasing trend. The United Kingdom, France, Sweden, Belgium, the Netherlands, and Spain had the higher CFR in the end of the period. Figure 3 displays the trend of CFR of COVID-19 in the countries.

**Discussion**

This study assessed the time trend of morbidity and mortality due to COVID-19 in all the six regions of the WHO from April 30, 2020, using the published data. The highest incidence rate of COVID-19 belonged to the European region and the lowest belonged to the African region. The reason for these differences between the regions may be differences in the demographic characteristics of population, restrictive policies, the disease epidemiologic status, and the last but not the least, preparedness of countries against disaster situations. One of the most effective probable reasons for high morbidity in the European region may be its high population density which has caused more people to become infected within a short time period.

The COVID-19 CFR was also different in WHO regions so that the lowest rate belonged to the African region with 3.74 and the highest belonged to the European region.
Many infected people may indicate mild symptoms of the disease and not be diagnosed as the confirmed cases of COVID-19. However, the real CFR of this disease is still ambiguous because many infected cases may have mild symptoms that did not undertake a diagnostic test. In order to reach a true estimate of CFR, it is necessary to conduct serology surveys in the large scale.\cite{26} Another reason may be the difference in population structure and their background diseases. Studies have indicated that background diseases,\cite{25} gender, and age\cite{25,26} are among the effective factors on the disease case fatality. These background diseases which are more prevalent among the elderly, increase COVID-19 severity.\cite{24,27}

Furthermore, the duration after reporting the first case and the incidence of disease are different in the countries, and this factor can effect on disease epidemiology and

| Country                  | Total cases | Total death |
|--------------------------|-------------|-------------|
| Coefficient | Robust SE | P | Coefficient | Robust SE | P | Coefficient | Robust SE | P |
| Australia | 320.49 | 10.89 | <0.001 | 10.05 | 0.53 | <0.001 | 0.07 | 0.00 | <0.001 |
| Belarus | 154.81 | 19.59 | <0.001 | 1.18 | 0.11 | <0.001 | 0.02 | 0.00 | <0.001 |
| Belgium | 570.81 | 37.06 | <0.001 | 77.86 | 7.10 | <0.001 | 0.21 | 0.01 | <0.001 |
| Brazil | 909.42 | 87.51 | <0.001 | 59.03 | 6.65 | <0.001 | 0.14 | 0.00 | <0.001 |
| Canada | 435.39 | 38.91 | <0.001 | 18.91 | 2.59 | <0.001 | 0.05 | 0.00 | <0.001 |
| Chile | 269.60 | 14.16 | <0.001 | 3.63 | 0.28 | <0.001 | 0.03 | 0.00 | <0.001 |
| China | 787.85 | 63.65 | <0.001 | 45.81 | 1.48 | <0.001 | 0.03 | 0.00 | <0.001 |
| Ecuador | 330.21 | 38.69 | <0.001 | 12.35 | 0.97 | <0.001 | 0.09 | 0.01 | <0.001 |
| France | 1420.38 | 83.09 | <0.001 | 229.18 | 18.96 | <0.001 | 0.19 | 0.01 | <0.001 |
| Germany | 1905.56 | 102.62 | <0.001 | 55.22 | 5.23 | <0.001 | 0.04 | 0.00 | <0.001 |
| India | 236.06 | 29.26 | <0.001 | 7.49 | 0.94 | <0.001 | 0.05 | 0.00 | <0.001 |
| Iran | 1579.86 | 44.38 | <0.001 | 100.24 | 2.88 | <0.001 | -0.21 | 0.11 | 0.06 |
| Ireland | 359.45 | 21.45 | <0.001 | 17.20 | 1.66 | <0.001 | 0.10 | 0.00 | <0.001 |
| Italy | 2603.75 | 110.47 | <0.001 | 339.00 | 16.82 | <0.001 | 0.20 | 0.01 | <0.001 |
| Japan | 116.81 | 10.47 | <0.001 | 2.62 | 0.31 | <0.001 | 0.03 | 0.00 | <0.001 |
| Mexico | 214.50 | 22.60 | <0.001 | 18.67 | 2.41 | <0.001 | 0.19 | 0.01 | <0.001 |
| The Netherlands | 731.22 | 28.32 | <0.001 | 85.21 | 4.25 | <0.001 | 0.25 | 0.01 | <0.001 |
| Pakistan | 216.24 | 17.47 | <0.001 | 4.44 | 0.44 | <0.001 | 0.04 | 0.00 | <0.001 |
| Peru | 470.06 | 48.99 | <0.001 | 12.61 | 1.39 | <0.001 | 0.07 | 0.00 | <0.001 |
| Poland | 237.76 | 11.53 | <0.001 | 10.24 | 0.79 | <0.001 | 0.08 | 0.00 | <0.001 |
| Portugal | 504.25 | 18.83 | <0.001 | 18.22 | 0.98 | <0.001 | 0.08 | 0.00 | <0.001 |
| Qatar | 160.01 | 17.31 | <0.001 | 0.20 | 0.01 | <0.001 | 0.00 | 0.00 | <0.001 |
| The Republic of Korea | 148.08 | 4.53 | <0.001 | 3.04 | 0.10 | <0.001 | 0.03 | 0.00 | <0.001 |
| Romania | 199.26 | 11.22 | <0.001 | 10.42 | 0.74 | <0.001 | 0.12 | 0.00 | <0.001 |
| Russian Federation | 680.04 | 101.56 | <0.001 | 6.14 | 0.99 | <0.001 | 0.01 | 0.00 | <0.001 |
| Saudi Arabia | 288.99 | 31.55 | <0.001 | 2.63 | 0.19 | <0.001 | 0.03 | 0.00 | <0.001 |
| Singapore | 94.94 | 14.22 | <0.001 | 0.14 | 0.01 | <0.001 | 0.00 | 0.00 | <0.001 |
| Spain | 2785.50 | 145.80 | <0.001 | 287.64 | 17.08 | <0.001 | 0.16 | 0.01 | <0.001 |
| Sweden | 203.56 | 14.85 | <0.001 | 21.40 | 2.22 | <0.001 | 0.15 | 0.01 | <0.001 |
| Switzerland | 594.78 | 18.55 | <0.001 | 25.09 | 1.18 | <0.001 | 0.08 | 0.00 | <0.001 |
| The United Kingdom | 1621.45 | 135.40 | <0.001 | 213.60 | 20.66 | <0.001 | 0.20 | 0.01 | <0.001 |
| Turkey | 2717.91 | 133.58 | <0.001 | 66.56 | 4.03 | <0.001 | 0.04 | 0.01 | <0.001 |
| Ukraine | 165.16 | 14.30 | <0.001 | 4.25 | 0.34 | <0.001 | -0.11 | 0.06 | 0.093 |
| The United Arab Emirates | 90.76 | 10.15 | <0.001 | 0.61 | 0.08 | <0.001 | 0.01 | 0.00 | <0.001 |
| The United States of America | 8491.39 | 747.34 | <0.001 | 385.05 | 43.38 | <0.001 | 0.05 | 0.00 | <0.001 |
| Selected countries | 25012.33 | 1812.38 | <0.001 | 1721.49 | 144.55 | <0.001 | 0.06 | 0.00 | <0.001 |
| Globe | 27003.95 | 1958.08 | <0.001 | 1903.38 | 203.98 | <0.001 | 0.06 | 0.01 | <0.001 |

SE=Standard error, CFR=Case fatality rate
its CFR. The time distance between diagnosis and death may be another explanation for differences in CFR among these regions. The detection process of cases and attributable deaths also may have different accuracy in the selected countries. In addition, the result of our study indicates that CFR in almost all countries had a positive pattern that showed the variability of this rate during the disease progression. Finally, differences in treatment facilities in the surveyed regions may be another explanation for CFR variation.

China had the most total number of confirmed cases among the countries located in the Western Pacific Region (WPRO). However, regarding incidence rate, Singapore had the first rank in this region. The time trend analysis results indicated China had the most average infected individuals daily followed by the Republic of Korea, Japan, and Singapore. In China, the time trend analysis indicated that from January 30, 2020, three days after editing the guideline of COVID-19 diagnosis and treatment, the number of confirmed cases has increased with a steeper slope. It seems that more expanding this guideline has led to the diagnosis of more new cases. The results of the current study indicated that the ascending slope of new cases take a flat trend after February 8, 2020. It seems that policies such as travel restrictions, quarantine, and isolation of cases are among the probable reasons. Japan was the third infected country with COVID-19 in WPRO it has enjoyed a decreasing morbidity and mortality trend in comparison with other countries that have been involved after it. The Japanese government has considered numerous limitations on arrival from China to Japan on January 7, 2020. Moreover, formulating diagnostic guidelines, active surveillance, and contact tracing were among other measures. It seems that performing these measures was successful in controlling the disease. Regarding another surveyed variable in the WPRO, China had the most CFR and Singapore had the least one. The time trend of CFR showed that this country had the lowest CFR globally, too. It seems that the experiences of Singapore in previous infectious outbreaks and implementation early social and public health interventions were effective to control COVID-19 in this country.

Iran had a higher number of confirmed cases of COVID-19 infections (93,657 cases) and deaths (5957 death) among the countries located in the Eastern Mediterranean Region (EMRO). However, after adjusting for the population, Qatar had the first position (highest incidence rate). The time trend of incidence rate in the EMRO showed that Iran had the most increasing trend next to Saudi Arabia, Pakistan, Qatar, and the United Arab Emirates. Compared with other countries in the world, Qatar had the second place. Asymptomatic patients due to their role in spreading the disease are among the most important probable causes of the increase in confirmed cases. The mortality trend also has an increasing slope in the following order: Pakistan, Saudi Arabia, the United Arab Emirates, and Qatar. CFR time trend analysis for Iran, showed that this rate had a negative trend that was not statistically significant at the level of 0.05. However, Iran’s CFR from the beginning of the outbreak until April 30 was 6.36 that was first among EMRO countries and sixth in the world. Access to treatment facilities is an important factor in survival chance of patients, especially for older ones or patients with comorbidities. It seems that inadequate access to these facilities at the beginning of this outbreak may be the reason of this finding. As stated above, the result of regression analysis showed a negative trend in CFR. In other words, the ascending trend of CFR started to descend, reaching to a real rate. This finding demonstrates that we cannot only judge on the information at the beginning of an outbreak.

Overall, the time distance between the confirmations of first cases may be the cause of difference between the countries located in the Eastern Mediterranean region. In other words, high number of confirmed cases and mortality of COVID-19 in Iran may be due to its sooner prevalence. On March 27, Iran tried to decrease the transmission chain through performing social distancing and limitation on traveling. It is necessary to point out that on the basis of a study assessing the effectiveness of interventions performed to control SARS disease, applying 90% travel restrictions would have a medium effect on the disease transmission chain when not accompanied by public health policies and behavioral change. The highest morbidity rate in the European region belonged to Spain and Belgium. The trend analysis showed that Spain, Turkey, Italy, and Germany had the highest slope of morbidity (incidence rate) since the beginning of the disease. On the basis of one study’s predictions on March 9, the number of infections in Italy, Spain, France, and Germany would continue to increase. The time trend of confirmed cases indicated that this prediction was true. The Spain government announced emergency status on March 14 and imposed country-level shutdown. Leaving the house was limited to providing food and medical supplies. It was expected that proper implementation of these policies decrease the disease slope. However, the disease reached to its peak on April 1; the trend of infected cases in Spain showed frequent up and down after its peak. The Italy government on March 8 tried to perform policies to restrict commuting in order to decrease the disease transmission to the healthy people. However, in this time we cannot evaluate the true impact of these public health interventions on control COVID-19.
In EURO, the highest CFR was in France and next in the United Kingdom, Belgium, and Italy. Analysis of CFR time trend showed that Italy, Spain, France, and the United Kingdom had the highest trend of CFR in this region. The most important cause of higher mortality rates in these countries is related to the population demographics. The present statistics indicate that 23% of Italian population is composed of higher than 65-year-old population. The other probable reasons for the higher mortality rate in Italy are an inaccurate definition of death due to COVID-19 and also the selected strategy to examine the suspected cases.\[37\]

The USA has had the highest COVID-19 morbidity in the WHO American region. However, the time trend analysis showed that the average of CFR in Mexico was the most among other Region of the Americas countries. Among the probable causes of higher incidence rate in the USA, we can mention a high focus on people screening on the basis of symptoms such as cough, fever, and shortness of breath.\[38\] However, not tracing health protocols of COVID-19 control caused high spreading rate of this disease in the USA.\[39\]

India was the only country in SEARO that we included in our study. Compared with other selected countries, it had the lowest disease incidence. However, there is some debates regarding the true number of infected cases in India. There is some argument that India’s diagnostic facilities for COVID-19 are limited.\[33\]

The discovery of effective treatment and vaccine for COVID-19 is a time-consuming process which it has estimated that obtaining an effective treatment needs a 10 years’ time.\[40\] There is no specific treatment for COVID-19 treatment at the present time,\[41\] so using other medicines used for similar diseases is an effective step.\[27\] However, prevention of the disease through controlling its development is the best solution.\[40,42,43\] The things that may be overlooked are cost-effectiveness and cost–benefit analysis of the probable vaccine discovered in future. Different countries place a vaccine in their national vaccination program on the basis of decision-making and budgeting presumptions and if possible vaccinations are not given publicly in future, their effectiveness will be greatly reduced.\[44\]

Applying other countries’ experiences is a recommended measure to get better results. China’s experience indicates that quarantine, social distancing, and isolation could control these epidemics. It is obvious that cooperation and coherence between countries are among the most important components in the successful control of COVID-19. In other words, formulating transparent and comprehensive policies on COVID-19 surveillance and control requires a comprehensive approach that includes local and international levels. Developing screening for all population and diagnosis of asymptomatic persons are the cornerstone in breaking the transmission chain. However, countries have not equal resources to prevention and to control the disease. In addition, countries with better surveillance systems probably have more valid data than other countries. Therefore, the reported cases in countries have not equal validity, and comparison of countries should be done with caution.

As stated above, it is necessary to determine disease epidemiology. Judging based on the current data should be with caution because many aspects of disease are still ambiguous. Tailoring successful prevention and treatment strategies is related to valid information regarding the nature of disease. Despite all these, differences in the morbidity and the mortality rates among selected countries could be attributed to various factors such as demographic differences of population structure, prevention actions, detection strategies, treatment facilities, and country’s ability in disaster management.

We investigated the trends of morbidity and mortality of COVID-19 by WHO regions and by countries which had more reported cases at the time of the study. This study is a unique one that investigated the time trends of reported cases and CFR in the world. This study finding is helpful to understanding the epidemiological aspects of the disease. This study along with assessing the time trend changes in COVID-19 morbidity and mortality has encountered with some limitations. First of all, the effect of other influential variables has not been assessed. The second limitation is that the true calculation of the CFR needs diagnostic of all positive cases, this is while due to asymptomatic cases, calculated CFR is exaggerated. Therefore, the CFR is probably overestimated in this study. Then, the interpretation of the results should be done with caution. Third limitation is related to data. As data of all included countries have not equal validity, the comparison of them should be done with cautious.

**Conclusion**

According to the results of the present study, over time, the number of patients with COVID-19 and the number of deaths from this disease are increasing. As mentioned earlier, many epidemiological aspects of the disease are still unknown, and it is difficult to answer questions about these characteristics. In addition, access to effective medicines and vaccines is a time-consuming process that doubles the concerns about the spread of the disease. In this situation, it will be more important to rely on the prevention of the disease. COVID-19 further reminds the very close relationship between countries in the world. Obviously, until the control of the disease, it is
necessary to apply public health policies accompanied by other policies at the national and global levels, while it is suggested to use the experience of successful countries for others.

**Acknowledgment**

We express our deepest gratitude to all the health workforce and researchers around the world, working hard to control COVID-19. In addition, we would like to thank Deputy of Research, Kermanshah University of Medical Sciences, for support of this study.

**Financial support and sponsorship**

This research was supported by Kermanshah University of Medical sciences, Iran (grant no. 981033). The study was approved by the Ethic Committee of Kermanshah University of Medical Sciences (ethical code: IR.KUMS.REC.1399.338).

**Conflicts of interest**

There are no conflicts of interest.

**References**

1. Cascella M, Rajnik M, Cuomo A, Dulebohn SC, Di Napoli R. Features, Evaluation and Treatment Coronavirus (COVID-19). In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK554767/. [Last updated on 2020 May 18].

2. Weston S, Frieman MB. COVID-19: Knowns, unknowns, and questions. mSphere 2020;5(2):e00203-20 DOI: 10.1128/mSphere.00203-20.

3. Adhikari SP, Meng S, Wu YJ, Mao YP, Ye RX, Wang QZ, et al. Epidemiology, causes, clinical manifestation and diagnosis, prevention and control of coronavirus disease (COVID-19) during the early outbreak period: A Scoping review. Infect Dis Poverty 2020;9:29.

4. Guo YR, Cao QD, Hong ZS, Tan YY, Chen SD, Jin HJ, et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak-an update on the status. Mil Med Res 2020;7:11.

5. Yoo JH. The fight against the 2019-nCoV outbreak: An arduous march has just begun. J Korean Med Sci 2019;35:e56.

6. Kamel Boulos MN, Geraghty EM. Geographical tracking and mapping of coronavirus disease COVID-19/severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) epidemic and associated events around the world: How 21st century GIS technologies are supporting the global light against outbreaks and epidemics. Int J Health Geogr 2020;19:8.

7. Lai CC, Shih TP, Ko WC, Tang HJ, Hsuéh PR. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. Int J Antimicrob Agents 2020;55:105924.

8. Schwartz DA. An analysis of 38 pregnant women with COVID-19, their newborn infants, and maternal-fetal transmission of SARS-CoV-2: Maternal coronavirus infections and pregnancy outcomes. Arch Pathol Lab Med 2020; DOI: 10.5858/arpa.2020-0901-SA.

9. Jin YH, Cai L, Cheng ZS, Cheng H, Deng T, Fan YP, et al. A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version). Mil Med Res 2020;7:4.

10. Shannugaraj B, Siriwattananon K, Wangkanont K, Phoolcharoen W. Perspectives on monoclonal antibody therapy as potential therapeutic intervention for Coronavirus disease-19 (COVID-19). Asian Pac J Allergy Immunol 2020;38:10-8.

11. Zhang Y. Analysis of Epidemiological characteristics of new coronavirus pneumonia. Chin J Epidemiol 2020;41:1-7.

12. Riazi J, Althauou CL. Pattern of early human-to-human transmission of Wuhan 2019 novel coronavirus (2019-nCoV), December 2019 to January 2020. Euro Surveill 2020;25:2000058.

13. Liu Y, Gayle AA, Wilder-Smith A, Rocklov J. The reproductive number of COVID-19 is higher compared to SARS coronavirus. J Travel Med 2020;27:taaa021.

14. Fan YV, Jamison DT, Summers LH. The inclusive cost of pandemic influenza risk. Natl Bureau Economic Res 2016;22137:0989-2937.

15. Programme UN. A socio-Economic Impact Assessment of the Zika virus in Latin America and the Caribbean: With a Focus on Brazil, Colombia and Suriname. New York, NY: United Nations Development Programme; 2017.

16. Lee BY, Alfaro-Murillo JA, Pappas AS, Asti L, Wedlock PT, Hotze PJ, et al. The potential economic burden of Zika in the continental United States. PLoS Negl Trop Dis 2017;11:e0005531.

17. Huber C, Finelli L, Stevens W. The economic and social burden of the 2014 ebola outbreak in West Africa. J Infect Dis 2018;218:698-704.

18. Qiu W, Chu C, Mao A, Wu J. The impacts on health, society, and economy of SARS and H7N9 outbreaks in China: A case comparison study. J Environ Public Health 2018;2018:1-7.

19. Colak S, Kandis H, Afacan MA, Erdogan MO, Gunes H, Kaya E, et al. Assessment of patients who presented to the emergency department with mushroom poisoning. Hum Exp Toxicol 2015;34:725-31.

20. OECD. COVID-19: SME Policy Responses; 16 March, 2020.

21. Driggin E, Madhavan MV, Bikdeli B, Chiuchi T, Laracy J, Bondi-Zoccai G, et al. Cardiovascular considerations for patients, health care workers, and health systems during the coronavirus disease 2019 (COVID-19) pandemic. J Am Coll Cardiol 2020;75:2352-71.

22. Moradi G, Piroozi B, Mohamadi-Bolbanabad A, Safari H, Shokri A, Rahimi R. Can judgments according to case fatality rate be correct all the time during epidemics? Estimated cases based on CFR in different scenarios and some lessons from early case fatality rate of coronavirus disease 2019 in Iran. Med J Islamic Republic Iran (MJIRI) 2020;34:178-82.

23. WHO. Coronavirus Disease 2019 (COVID-19) Situation Report – 101; 30 March, 2020.

24. Anderson RM, Heesterbeek H, Klinkenberg D, Hollingsworth TD. How will country-based mitigation measures influence the course of the COVID-19 epidemic? Lancet 2020;395:931-4.

25. Fisher D, Heymann DJ. Q&A: The novel coronavirus outbreak causing COVID-19. BMC Medicine 2020;18:1-3.

26. LiQ, GuanX, WuP, WangX, ZhouL, TongY, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med 2020;382:1199-207.

27. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497-506.

28. Battegay M, Kuehl R, Tschudin-Sutter S, Hirsch HH, Widmer AF, Neher RA. 2019-novel coronavirus (2019-nCoV): Estimating the case fatality rate—a word of caution. Swiss Med Weekly 2020:150:w2023.

29. National Health Commission of the People’s Republic of China. Diagnosis and Treatment Guideline on Pneumonia Infection with 2019 Novel Coronavirus (5th Trial ed). Available from: http://www.nhc.gov.cn/xcs/zhengwenci/202002/d4b895337e194458fd728cfa1e3e13a.shtml. [Last accessed on 2020 Feb 18].

30. Zhang J, Litvinova M, Wang W, Wang Y, Deng X, Chen X, et al. Evolving epidemiology of novel coronavirus diseases 2019 and
possible interruption of local transmission outside Hubei Province in China: A descriptive and modeling study. medRxiv 2020; doi: 10.1101/2020.02.21.20026328.

31. Wong JEL, Leo YS, Tan CC. COVID-19 in Singapore-current experience: Critical global issues that require attention and action. JAMA 2020;323(13):1243-4.

32. Porcheddu R, Serra C, Kelvin D, Kelvin N, Rubino S. Similarity in case fatality rates (CFR) of COVID-19/SARS-COV-2 in Italy and China. J Infect Dev Ctries 2020;14:125-8.

33. Drake JM, Chew SK, Ma S. Societal learning in epidemics: Intervention effectiveness during the 2003 SARS outbreak in Singapore. PLoS One 2006;1:e20.

34. Yuan J, Li M, Lv G, Lu ZK. Monitoring transmissibility and mortality of COVID-19 in Europe. Int J Infect Dis 2020;95:311-5.

35. India P. Future of India-The Winning Leap; 2014.

36. Remuzzi A, Remuzzi GJ. COVID-19 and Italy: What next? Health policy 2020;395:1225-8.

37. Klompas M. Coronavirus Disease 2019 (COVID-19): Protecting Hospitals From the Invisible. Ann Intern Med 2020;172:619-20.

38. Parodi SM, Liu VX. From containment to mitigation of COVID-19 in the US. JAMA 2020;323:1441-2.

39. Pillaiyar T, Meenakshisundaram S, Manickam MJ. Recent discovery and development of inhibitors targeting coronaviruses. Drug Discov Today 2020;25:668-88.

40. CDC U. Novel coronavirus - Information for Healthcare Professionals; 2020. Available from: https://www.cdc.gov/coronavirus/2019-ncov/hcp/index.html. [Last accessed on 2020 Mar 29].

41. Lu H. Drug treatment options for the 2019-new coronavirus (2019-nCoV). Biosci Trends 2020;14:69-71.

42. Sheahan TP, Sims AC, Leist SR, Schäfer A, Won J, Brown AJ, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun 2020;11:222.

43. Goudarzi R, Tasavon Gholamhoseini M, Amini S, Nakhaei M, Dehnavieh R. Estimating the cost of vaccination in southeastern Iran. Hum Vaccin Immunother 2020;1-7. https://doi.org/10.1080/21645515.2020.1725357.

44. World Health Organization. Coronavirus Disease 2019 (COVID-19) Situation Report-44. Available from: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200304-sitrep-44-covid-19.pdf?sfvrsn=783b4e9d_2. [Last accessed on 2020 Mar 04; Last accessed on 2020 Mar 05].